JP2019142962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142962A5 JP2019142962A5 JP2019087976A JP2019087976A JP2019142962A5 JP 2019142962 A5 JP2019142962 A5 JP 2019142962A5 JP 2019087976 A JP2019087976 A JP 2019087976A JP 2019087976 A JP2019087976 A JP 2019087976A JP 2019142962 A5 JP2019142962 A5 JP 2019142962A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- acid sequence
- genotype
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004196 processed proteins & peptides Human genes 0.000 claims 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims 61
- 229920001184 polypeptide Polymers 0.000 claims 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims 53
- 241000711549 Hepacivirus C Species 0.000 claims 40
- 239000000833 heterodimer Substances 0.000 claims 14
- 230000002163 immunogen Effects 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108700008783 Hepatitis C virus E1 Proteins 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000863 peptide conjugate Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823712P | 2013-05-15 | 2013-05-15 | |
| US61/823,712 | 2013-05-15 | ||
| US201361887229P | 2013-10-04 | 2013-10-04 | |
| US61/887,229 | 2013-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Division JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001926A Division JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142962A JP2019142962A (ja) | 2019-08-29 |
| JP2019142962A5 true JP2019142962A5 (enExample) | 2020-02-27 |
Family
ID=54054625
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2024130501A Pending JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2024130501A Pending JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210145963A9 (enExample) |
| EP (2) | EP2996718B1 (enExample) |
| JP (5) | JP2016520077A (enExample) |
| CN (2) | CN112999344A (enExample) |
| AU (3) | AU2014385320B2 (enExample) |
| CA (1) | CA2909586C (enExample) |
| CL (1) | CL2015003333A1 (enExample) |
| WO (1) | WO2015132619A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11186615B2 (en) * | 2015-10-08 | 2021-11-30 | The Governors Of The University Of Alberta | Hepatitis C virus E1/E2 heterodimers and methods of producing same |
| WO2018055535A2 (en) * | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
| CN110381996A (zh) * | 2016-10-11 | 2019-10-25 | 艾伯塔大学理事会 | 包含环状二核苷酸或古细菌脂质体作为佐剂的丙型肝炎病毒免疫原性组合物及其使用方法 |
| US12048742B2 (en) | 2018-03-16 | 2024-07-30 | The Governors Of The University Of Alberta | Hepatitis C virus peptide compositions and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| PT773957E (pt) | 1994-07-29 | 2005-11-30 | Chiron Corp | Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
| ATE437951T1 (de) | 1997-05-06 | 2009-08-15 | Novartis Vaccines & Diagnostic | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 |
| DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| ATE432348T1 (de) | 1997-06-06 | 2009-06-15 | Univ California | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| CZ301212B6 (cs) | 1998-10-16 | 2009-12-09 | Smithkline Beecham Biologicals S. A. | Vakcinacní prostredek |
| EP1162999B1 (en) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| TR200103018T2 (tr) | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| JP2003509473A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| KR20020048942A (ko) | 1999-09-24 | 2002-06-24 | 장 스테판느 | 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트 |
| JP4370161B2 (ja) * | 2001-06-29 | 2009-11-25 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｈｃｖｅ１ｅ２ワクチン組成物 |
| US7348011B2 (en) * | 2005-06-10 | 2008-03-25 | Sudershan Biotech Ltd. | Hepatitis C virus vaccine |
| WO2007041432A2 (en) | 2005-09-30 | 2007-04-12 | Novartis Vaccines And Diagnostics, Inc. | Cross-neutralization of hcv with recombinant proteins |
| US8603468B2 (en) * | 2007-11-06 | 2013-12-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Neutralization of HCV |
| WO2014060851A2 (en) * | 2012-10-05 | 2014-04-24 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
-
2014
- 2014-05-15 AU AU2014385320A patent/AU2014385320B2/en active Active
- 2014-05-15 EP EP14884476.4A patent/EP2996718B1/en active Active
- 2014-05-15 EP EP19215826.9A patent/EP3689375A1/en not_active Withdrawn
- 2014-05-15 WO PCT/IB2014/001972 patent/WO2015132619A1/en not_active Ceased
- 2014-05-15 JP JP2016513459A patent/JP2016520077A/ja not_active Withdrawn
- 2014-05-15 US US14/783,699 patent/US20210145963A9/en not_active Abandoned
- 2014-05-15 CN CN202110252076.3A patent/CN112999344A/zh active Pending
- 2014-05-15 CA CA2909586A patent/CA2909586C/en active Active
- 2014-05-15 CN CN201480027001.3A patent/CN105263517B/zh active Active
-
2015
- 2015-11-13 CL CL2015003333A patent/CL2015003333A1/es unknown
-
2019
- 2019-05-08 JP JP2019087976A patent/JP2019142962A/ja not_active Withdrawn
-
2020
- 2020-01-10 AU AU2020200216A patent/AU2020200216A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021001926A patent/JP2021059596A/ja active Pending
-
2022
- 2022-02-04 AU AU2022200747A patent/AU2022200747A1/en not_active Abandoned
- 2022-03-23 US US17/702,231 patent/US20230098265A1/en not_active Abandoned
- 2022-08-31 JP JP2022137454A patent/JP2022172244A/ja active Pending
-
2023
- 2023-11-27 US US18/520,057 patent/US20240316186A1/en active Pending
-
2024
- 2024-08-07 JP JP2024130501A patent/JP2024156917A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142962A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| AU772617B2 (en) | Vaccine compositions | |
| RU2003130955A (ru) | Кор-гликозилированные оболочечные белки вируса гепатита с (hcv) | |
| JP2012501959A5 (enExample) | ||
| JP2014502156A5 (enExample) | ||
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| JP2022172244A5 (enExample) | ||
| JP6676661B2 (ja) | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 | |
| Mohan et al. | Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1 | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| JP2004537308A5 (enExample) | ||
| EP2374811A1 (en) | IgG Fc/HIV-gp120/c3d fusion protein | |
| TWI507413B (zh) | 脂質化多抗原表位疫苗 | |
| JP2010535504A5 (enExample) | ||
| WO2024047090A3 (en) | Modified virus-like particles of cmv | |
| RU96108781A (ru) | Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1 | |
| US20200353069A1 (en) | Improved hiv envelope glycoprotein immunogens | |
| Yamashita et al. | Lack of immunodominance in the T cell response to herpes simplex virus glycoprotein D after administration of infectious virus. | |
| CN104837498A (zh) | 针对丙型肝炎病毒的嵌合疫苗抗原 | |
| WO2002020048A1 (en) | A classical swine fever virus epitope vaccine and its producing method | |
| Shao et al. | DNA fragment encoding human IL-1β 163–171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease | |
| JP2006525786A5 (enExample) | ||
| CN118574640A (zh) | 有限化慢性乙肝的核苷（酸）类药物治疗的药物及方法 | |
| JP2003528614A5 (enExample) |